Burden of significant liver damage in people living with HIV after microelimination of the hepatitis C virus

Santos, Mónica; Corma-Gómez, Anaïs; Fernandez-Fuertes, M.; González‐Serna, Alejandro; Rincón, Pilar; Real, Luis Miguel; Pineda, Juan A; Macı́as, Juan

doi:10.1016/j.jinf.2022.11.004

Cited by 6 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, AIDS patients are prone to liver damage when receiving drug treatment, especially when multiple drugs are used in combination. Research has found that liver disease has gradually become the most common complication in AIDS mortality, accounting for 14% to 18% of all AIDS deaths [7][8][9]. Liver damage in AIDS patients mainly includes abnormal liver function, liver failure, liver fibrosis, liver cirrhosis, primary liver cancer, and end-stage liver disease [10,11].…”

Section: Introductionmentioning

confidence: 99%

Discovery of Dolutegravir Derivative against Liver Cancer via Inducing Autophagy and DNA Damage

Hou,

Yan,

et al. 2024

Molecules

View full text Add to dashboard Cite

We introduced a terminal alkyne into the core structure of dolutegravir, resulting in the synthesis of 34 novel dolutegravir-1,2,3-triazole compounds through click chemistry. These compounds exhibited remarkable inhibitory activities against two hepatocellular carcinoma cell lines, Huh7 and HepG2. Notably, compounds 5e and 5p demonstrated exceptional efficacy, particularly against Huh7 cells, with IC50 values of 2.64 and 5.42 μM. Additionally, both compounds induced apoptosis in Huh7 cells, suppressed tumor cell clone formation, and elevated reactive oxygen species (ROS) levels, further promoting tumor cell apoptosis. Furthermore, compounds 5e and 5p activated the LC3 signaling pathway, inducing autophagy, and triggered the γ-H2AX signaling pathway, resulting in DNA damage in tumor cells. Compound 5e exhibited low toxicity, highlighting its potential as a promising anti-tumor drug.

show abstract